Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

A Phase 1a, Repeat-Dose Escalation Study to Investigate the Safety and Tolerability of a 7-Day Repeated Dose of Retinoid QLT091001 in Healthy Volunteers

Healthy volunteer subjects will receive retinoid QLT091001 once-daily for 7 days for safety observation.

Inclusion Criteria:

• Healthy subjects with ECG within normal limits and normal blood pressure and resting heart rate

Exclusion Criteria:

• Subjects with any clinically important abnormal physical finding at screening.
• Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of baseline.
• Female subjects who are either pregnant or lactating.